Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cendakimab in Eosinophilic Esophagitis
NCT02098473Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2014
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of cendakimab in eosinophilic esophagitis (EoE), sponsored by Celgene Corporation. Started Aug 2014; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT02098473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098473.